The approval dates back to April 2009, when the European Commission followed the recommendation of the Committee for Human Medicinal Products (CHMP) and approved catumaxomab for the i.p. treatment of malignant ascites in patients with EpCAM+ carcinomas resistant to standard treatments. Here, EPCAM is linked to cancer.